IONS - Ionis Pharmaceuticals, Inc.
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.About Ionis Pharmaceuticals, Inc.For three decades, Ionis has invented me.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw. com or 646-581-9980, ext. 7980.
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
SAN FRANCISCO, July 14, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
Ionis Pharmaceuticals (NASDAQ: IONS) investors absorbed a >20% share decline after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint. Levi & Korsinsky is investigating potential securities law violations.
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical effi.
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
NEW YORK--(BUSINESS WIRE)--Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The CARDIO.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrome, a rare, severe and lifelong neurological disorder. Dravet syndrome typically begins in infancy and is associated with prolonged seizures, developmental delays, cognitive impairments and an increased risk of sudden death. “The first participa.
Shares of Ionis Pharmaceuticals (NASDAQ:IONS | IONS Price Prediction) are down 9% intraday, changing hands near $58.30 after opening the session at $64.27.
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.
/PRNewswire/ -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) dropped more than 20% pre-market on July 9, 2026, after the Company announced that its
Ionis Pharmaceuticals told investors its CARDIO-TTRansform program was on track to deliver landmark data -- then the Phase-3 trial missed its primary endpoint. Levi & Korsinsky is investigating.
AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) on Thursday said their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.